This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Bebetter Med Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Mingsheng Lin: Innovator in Anti-Tumor Drug Development
Introduction
Mingsheng Lin is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor drugs. His innovative work focuses on compounds that target specific mutations in epidermal growth factor receptors (EGFR), which are crucial in the treatment of certain types of cancer.
Latest Patents
Mingsheng Lin holds a patent for a compound titled "2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof." This patent describes a compound that selectively suppresses the activity of mutant EGFRs, including the T790M mutation, which is often associated with non-small cell lung cancer (NSCLC). The compound demonstrates a high level of selectivity and a weak suppression effect on wild-type EGFR, making it a promising candidate for drug development aimed at treating EGFR mutant tumors.
Career Highlights
Mingsheng Lin is currently associated with Bebetter Med Inc., where he continues to advance his research in the pharmaceutical sector. His work has the potential to significantly impact the treatment landscape for patients with specific EGFR mutations. With a focus on innovative drug development, Lin's contributions are paving the way for more effective cancer therapies.
Collaborations
Mingsheng Lin collaborates with notable colleagues, including Yuanhui Qing and Yanyan Wang. These partnerships enhance the research and development efforts at Bebetter Med Inc., fostering an environment of innovation and scientific advancement.
Conclusion
Mingsheng Lin's work in developing targeted anti-tumor drugs exemplifies the importance of innovation in the pharmaceutical industry. His patented compound represents a significant step forward in the treatment of cancers associated with EGFR mutations. Through his research and collaborations, Lin is making a meaningful impact on cancer therapy.